ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Public ClinicalTrials.gov record NCT02136914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once nightly at bedtime for the treatment of levodopa induced dyskinesia (LID) in subjects with Parkinson's disease (PD). The novel pharmacokinetic profile of ADS-5102 is expected to achieve i) maximal concentrations in the early morning through mid-day, when LID can be troublesome, and ii) lower concentrations in the evening, potentially reducing the negative impact of amantadine on sleep. This pharmacokinetic profile could enable higher doses to be tolerated with a once-nightly ER formulation than can be tolerated with an immediate-release formulation. The once-nightly dosing regimen may also provide enhanced convenience and compliance. In a previous clinical study, ADS-5102 met its primary endpoint; LID was significantly reduced as measured by the change in UDysRS score over 8 weeks vs. placebo.
Study identification
- NCT ID
- NCT02136914
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 126 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 30 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2014 (Type not available)
- Primary completion
- Dec 2015 (Actual)
- Completion
- Dec 2015 (Actual)
- Last update posted
- Feb 6, 2018
2014 – 2015
United States locations
- U.S. sites
- 43
- U.S. states
- 21
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Phoenix | Arizona | 85013 | — |
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Sun City | Arizona | 85351 | — |
| Not listed | Fountain Valley | California | 92708 | — |
| Not listed | Pasadena | California | 91105 | — |
| Not listed | Reseda | California | 91335 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | Torrance | California | 90505 | — |
| Not listed | Ventura | California | 93003 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Manchester | Connecticut | 06040 | — |
| Not listed | Boca Raton | Florida | 33486 | — |
| Not listed | Gainesville | Florida | 32607 | — |
| Not listed | Naples | Florida | 34102 | — |
| Not listed | Port Charlotte | Florida | 33980 | — |
| Not listed | Sunrise | Florida | 33351 | — |
| Not listed | Tampa | Florida | 33613 | — |
| Not listed | Weston | Florida | 33331 | — |
| Not listed | Atlanta | Georgia | 30329 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Des Moines | Iowa | 50309 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Bingham Farms | Michigan | 48025 | — |
| Not listed | West Bloomfield | Michigan | 48322 | — |
| Not listed | Golden Valley | Minnesota | 55427 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Albany | New York | 12208 | — |
| Not listed | Commack | New York | 11725 | — |
| Not listed | New York | New York | 10003 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Raleigh | North Carolina | 27607 | — |
| Not listed | Cincinnati | Ohio | 45219 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Toledo | Ohio | 43614 | — |
| Not listed | Tulsa | Oklahoma | 74136 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | Houston | Texas | 77030-1 | — |
| Not listed | Houston | Texas | 77030-2 | — |
| Not listed | Kirkland | Washington | 98034 | — |
| Not listed | Milwaukee | Wisconsin | 53233 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02136914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2018 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02136914 live on ClinicalTrials.gov.